Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Phase I/II Trial of the Combination of Selinexor (SEL), Liposomal Doxorubicin (DOX) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma PDF (1.28 MB) Read MorePresentation Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) PDF (387.18 KB) Read MorePresentation A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone (SRd) in Patients with Relapsed / Refractory Multiple Myeloma PDF (1,000.31 KB) Read MorePresentation A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3- mutated Acute Myeloid Leukemia (AML) PDF (590.56 KB) Read MorePaper Promising Activity Of Selinexor In The Treatment Of A Patient With Refractory Diffuse Large B-Cell Lymphoma And Central Nervous System Involvement External Link Read MorePaper Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom’s macroglobulinemia External Link Read MorePresentation A Phase 1 Study of Selinexor in Combination with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers PDF (738.99 KB) Read MorePresentation First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL PDF (3.83 MB) Read MorePresentation Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin PDF (3.25 MB) Read MorePresentation Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma PDF (908.32 KB) Read More Previous 1 2 3 4 5 … 22 Next